2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma

Annals of Oncology

Volumn 7, Issue 8, 1996, Pages 793-799

  Betticher, D C ^a,e   Zucca, E ^b   Von Rohr, A ^a   Egger, T ^a   Radford, J A ^c   Ambrosetti, A ^d   Burki K ^e   Rufener, B ^f   Hsu Schmitz, S F ^f   Cerny, T ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b OSPEDALE SAN GIOVANNI   (Switzerland)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d POLICLINICO BORGO ROMA   (Italy)

^e UNIVERSITY OF BERN   (Switzerland)

^f SIAK Coordinating Center   (Switzerland)

Author keywords

2 Chlorodeoxyadenosine; bcl 2 rearrangement; Cladribine; Follicular lymphoma; t(14; 18) chromosomal translocation

Indexed keywords

CLADRIBINE; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE REARRANGEMENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 10244219905     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010757     Document Type: Article

References (36)

1. Gallagher CJ, Lister TA. Follicular non-Hodgkin's lymphoma. Bailleres Clin Haematol 1987; 1: 141-55.
2. Spinolo JA, Cabanillas F, Dixon DO et al. Therapy of relapsed or refractory low-grade follicular lymphomas: Factors associated with complete remission, survival and time to treatment failure. Ann Oncol 1992; 3: 227-32.
3. Rohatiner AZS, Lister TA. The management of follicular lymphomas. Drugs 1994; 47 (Suppl 6): 10-8.
4. Johnson PWM, Rohatiner AZS, Whelan JS et al. Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 1996; 13: 140-7.
5. Gisselbrecht C, Cosset JM. Treatment of low-grade non-Hodgkin's lymphomas. In Solal-Céligny P, Brousse N, Reyes F et al. (eds): Non-Hodgkin's Lymphomas. London: Manson 1993; 317-36.
6. Rohatiner AZS, Johnson PWM, Price CGA et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12: 1177-84.
7. Lambrechts AC, Hupkes PE, Dorssers LCJ et al. Clinical significance of t(14;18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission. J Clin Oncol 1994; 12: 1541-6.
8. Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after auto-logous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-57.
9. Gribben JG, Neuberg D, Barber M et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994; 83: 3800-7.
10. Johnson PWM, Price CGA, Smith T et al. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 1994; 12: 798-805.
11. Cheson BD. New chemotherapeutic agents for the treatment of low-grade non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 96-110.
12. Pott-Hoeck C, Hiddemann W. Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. Ann Oncol 1995; 6: 421-33.
13. Saven A, Piro LD. 2-Chlorodeoxyadenosine: A newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Int Med 1994; 120: 784-91.
14. Hickish T, Serafinowski P, Cunningham D et al. 2′-Chlorodeoxyadenosine: Evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer 1993; 67: 139-43.
15. Kay AC, Saven A, Carrera CJ et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 1992; 10: 371-7.
16. Hoffman M, Tallman MS, Hakimian D et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 788-92.
17. Betticher DC, Fey MF, Von Rohr A et al. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Ann Oncol 1994; 5: 57-64.
18. World Health Organization. Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 48. Geneva: WHO 1979.
19. Coiffier B, Bastion Y, Berger F et al. Prognostic factors in follicular lymphomas. Semin Oncol 1993; 20: 89-95.
20. Liliemark J, Juliusson G. Intermittent infusion of cladribine (CdA) in previously treated low grade non-Hodgkin's lymphoma (LG-NHL): Response, toxicity and survival. Proc Am Soc Clin Oncol 1995; 14: 191.
21. Khan A, Schiller G, Levine A et al. 2-Chloro-2′-deoxyadenosine (2-CDA), an active agent in the treatment of advanced relapsed or refractory low to intermediate grade non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1994; 13: 386.
22. Rummel M, Leimer L, Hoffknecht M et al. 2-CDA treatment of untreated low grade non-Hodgkin lymphomas - preliminary results of a phase II study. Blood 1995; 86 (Suppl 1): 56a.
23. Kong L, Rademarker A, Hakimian D et al. Long-term followup after 2-chlorodeoxyadenosine therapy in previously treated advanced non-Hodgkin's lymphoma (NHL). Proc Natl Acad Sci USA 1996; 15:425 (Abstr 1311).
24. Fridrik MA, Linkesch W, Jäger G et al. Response and toxicity of cladribine (2-CDA) as first line treatment of low-grade non-Hodgkin's lymphomas (NHL). Preliminary data of an Austrian multicentre trial. Blood 1995; 86 (Suppl J): 56a.
25. Piro LD, Petroni G, Barcos M et al. Bolus infusion 2-chlorodeoxyadenosine (2-CDA) as first-line therapy of low grade non-Hodgkin's lymphoma (NHL): CALGB 9153. Blood 1995; 86 (Suppl 1): 274a.
26. Jäger G, Fridrik MA, Kienzer HJ et al. Response and toxicity of cladribine (2-CDA) as first line treatment of low grade non-Hodgkin's lymphomas (NHL). Preliminary data of an Austrian multicenter trial. Proc Natl Acad Sci USA 1996; 15: 410 (Abstr 1253).
27. Saven A, Emanuele S, Kosty M et al. 2-Chlorodeoxyadenosine activity in patients with untreated indolent non-Hodgkin's lymphoma. Blood 1995; 86: 1710-6.
28. Solal-Céligny P, Brice P, Brousse N et al. Phase II trial of fludarabine monophosphate as a first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the groupe d'étude des lymphomes de l'adulte. J Clin Oncol 1996; 14: 514-9.
29. Cotter F, Price C, Zucca E et al. Direct sequence analysis of the 14q+ and 18q- chromosome junctions in follicular lymphoma. Blood 1990; 76: 131-5.
30. Yuan R, Dowling P, Zucca E et al. Detection of bcl-2/JH rearrangement in follicular and diffuse lymphoma: Concordant results of peripheral blood and bone marrow analysis at diagnosis. Br J Cancer 1993; 67: 922-5.
31. Turner GE, Ross FM, Krajewski AS. Detection of t(14;18) in British follicular lymphoma using cytogenetics, Southern blotting and the polymerase chain reaction. Br J Haematol 1995; 89: 223-5.
32. Price CGA, Meerabux J, Murtagh S et al. The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Oncol 1991; 9: 1527-32.
33. Gribben JG, Freedman AS, Woo SD et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275-80.
34. Keating MJ. Immunosuppression with purine analogues - the flip side of the gold coin. Ann Oncol 1993; 4: 347-8.
35. Carson AD, Wasson DB, Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2-deoxyadenosine. Proc Natl Acad Sci 1984; 81: 2232-6.
36. Saven A, Lemon RH, Kosty M et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995; 13: 570-4.